|
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), Genentech, Inc. (NYSE: DNA) and Amgen, Inc. (NYSE: AMGN).
See the latest posts to the Analyst Blog: http://www.zacks.com/blog/post_info.html?g=6
Here are highlights from Tuesday’s Analyst Blog:
Avoid Amylin Pharma Shares
At this time the valuation on Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) is not attractive. The top-line is being driven by sales of two diabetes drugs, Byetta and Symlin. Sales of both drugs have disappointed over the past several quarters, but the Amylin story is tied to the success or failure of phase III potential blockbuster, Exenatide LAR. Data on LAR was presented in October 2007. We classified the data as good, but not great.
The stock is trading at 15x our 2012 EPS estimate well above the peer-group at 10x and that estimate assumes LAR posts sales over $1.8 billion. In the meantime, there are few catalysts and operating expenses are soaring. Amylin currently trades at 15x our 2012 EPS estimate of $2.04. The 2012 multiple is a 50% premium to the large-cap pharma / biotechnology peer-group average of 10x 2012 EPS. The peer-group consists of several large-cap bellwethers including Eli Lilly (NYSE: LLY)(8x), Merck (NYSE: MRK)(7x), Genentech, Inc. (NYSE: DNA)(9x) and Amgen, Inc. (NYSE: AMGN)(6x).
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
|
(0 voto)
